Table 2.
Phase I/II Ultrahypofractionation Trials: Schedules and Equivalent Total Doses in 2-Gy Fractions
| Fractionation (tot.does/fx size/#fx) | Total Dose Equivalent in 2Gy Fractions (NTD2) | No. of PTS | Institution | References | |
|---|---|---|---|---|---|
| Alpha/Beta = 1.5 (tumor) | Alpha/Beta = 3 (late effects) | ||||
| 33.5 Gy/6.7 Gy/5 fx | 78 Gy | 64.9 Gy | 40 | Virginia Mason | Madsen et al36 |
| 36.25 Gy/7.25 Gy/5 fx | 90.6 Gy | 74.3 Gy | 23 (ongoing) | Stanford | Pawlicki et al37 |
| 42.7 Gy/6.1 Gy/7 fx | 92.7 Gy | 77.7 Gy | 105 | Umea | Widmark (personal communication, 2008) |
| 35 Gy/7 Gy/5 fx | 85.1 Gy | 70 Gy | 30 (ongoing) | University of Toronto | Tang et al38 |
| 47.5 Gy/9.5 Gy/5 fx | 149 Gy* | 118 Gy | 15 | UTSW, Dallas | Timmerman (personal communication, 2008) |
| 50 Gy/10 Gy/5 fx | 164 Gy | 130 Gy | 10 (ongoing) | ||
| 52.5 Gy/10.5 Gy/5 fx | 180 Gy | 142 Gy | – | ||
NTD doses based on linear-quadratic modeling may overpredict NTDs for large fractions, as in the UTSW trial.